Name | Number of supported studies | Average coverage | |
---|---|---|---|
type II pneumocyte | 7 studies | 28% ± 11% | |
oligodendrocyte | 5 studies | 24% ± 5% | |
epithelial cell | 3 studies | 16% ± 1% | |
GABAergic neuron | 3 studies | 33% ± 2% | |
glutamatergic neuron | 3 studies | 42% ± 5% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 4 studies | 34% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1612.52 | 1445 / 1445 | 100% | 19.81 | 183 / 183 |
lung | 100% | 3188.14 | 578 / 578 | 100% | 23.66 | 1154 / 1155 |
prostate | 100% | 2066.98 | 245 / 245 | 99% | 17.22 | 499 / 502 |
brain | 100% | 1618.73 | 2637 / 2642 | 100% | 16.41 | 702 / 705 |
ovary | 100% | 2089.04 | 180 / 180 | 99% | 15.24 | 427 / 430 |
breast | 100% | 2070.32 | 459 / 459 | 99% | 23.42 | 1107 / 1118 |
stomach | 100% | 1369.81 | 359 / 359 | 99% | 16.85 | 282 / 286 |
pancreas | 100% | 963.98 | 327 / 328 | 99% | 13.17 | 176 / 178 |
intestine | 100% | 2018.38 | 966 / 966 | 98% | 15.72 | 519 / 527 |
kidney | 100% | 2074.97 | 89 / 89 | 98% | 26.02 | 881 / 901 |
thymus | 100% | 1938.05 | 653 / 653 | 98% | 13.19 | 590 / 605 |
bladder | 100% | 2104.67 | 21 / 21 | 97% | 14.47 | 491 / 504 |
uterus | 100% | 2160.84 | 170 / 170 | 97% | 15.12 | 446 / 459 |
skin | 100% | 2108.00 | 1809 / 1809 | 97% | 20.88 | 457 / 472 |
liver | 100% | 1666.31 | 226 / 226 | 94% | 11.62 | 381 / 406 |
adrenal gland | 100% | 1777.28 | 258 / 258 | 93% | 11.28 | 214 / 230 |
adipose | 100% | 2021.94 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1997.84 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 14.44 | 29 / 29 |
muscle | 100% | 2638.26 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 1940.32 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 13.46 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 4.94 | 1 / 1 |
heart | 97% | 1292.53 | 833 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 90% | 11.40 | 72 / 80 |
peripheral blood | 80% | 1146.09 | 740 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0046655 | Biological process | folic acid metabolic process |
GO_1904042 | Biological process | negative regulation of cystathionine beta-synthase activity |
GO_0009086 | Biological process | methionine biosynthetic process |
GO_0033353 | Biological process | S-adenosylmethionine cycle |
GO_0050667 | Biological process | homocysteine metabolic process |
GO_0043418 | Biological process | homocysteine catabolic process |
GO_0045111 | Cellular component | intermediate filament cytoskeleton |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0071949 | Molecular function | FAD binding |
GO_0070402 | Molecular function | NADPH binding |
GO_0016723 | Molecular function | oxidoreductase activity, acting on metal ions, NAD or NADP as acceptor |
GO_0030586 | Molecular function | [methionine synthase] reductase (NADPH) activity |
GO_0010181 | Molecular function | FMN binding |
GO_0050660 | Molecular function | flavin adenine dinucleotide binding |
GO_0005515 | Molecular function | protein binding |
GO_0003958 | Molecular function | NADPH-hemoprotein reductase activity |
Gene name | MTRR |
Protein name | Methionine synthase reductase (MSR) (EC 1.16.1.8) (Aquacobalamin reductase) (AqCbl reductase) 5-methyltetrahydrofolate-homocysteine methyltransferase reductase |
Synonyms | |
Description | FUNCTION: Key enzyme in methionine and folate homeostasis responsible for the reactivation of methionine synthase (MTR/MS) activity by catalyzing the reductive methylation of MTR-bound cob(II)alamin . Cobalamin (vitamin B12) forms a complex with MTR to serve as an intermediary in methyl transfer reactions that cycles between MTR-bound methylcob(III)alamin and MTR bound-cob(I)alamin forms, and occasional oxidative escape of the cob(I)alamin intermediate during the catalytic cycle leads to the inactive cob(II)alamin species (Probable). The processing of cobalamin in the cytosol occurs in a multiprotein complex composed of at least MMACHC, MMADHC, MTRR and MTR which may contribute to shuttle safely and efficiently cobalamin towards MTR in order to produce methionine . Also necessary for the utilization of methyl groups from the folate cycle, thereby affecting transgenerational epigenetic inheritance (By similarity). Also acts as a molecular chaperone for methionine synthase by stabilizing apoMTR and incorporating methylcob(III)alamin into apoMTR to form the holoenzyme . Also serves as an aquacob(III)alamin reductase by reducing aquacob(III)alamin to cob(II)alamin; this reduction leads to stimulation of the conversion of apoMTR and aquacob(III)alamin to MTR holoenzyme . . |
Accessions | ENST00000506877.1 A0A3P9MRF3 ENST00000510279.5 ENST00000502550.5 ENST00000514369.5 D6RF21 H0Y963 ENST00000514220.5 Q9UBK8 ENST00000264668.6 [Q9UBK8-1] D6RAY3 ENST00000512217.5 H0Y9Q0 ENST00000510525.5 ENST00000513439.5 H0Y8S9 D6RAZ2 ENST00000511461.5 ENST00000440940.7 [Q9UBK8-2] D6RGC7 ENST00000503550.5 D6RIS8 H0Y9D5 ENST00000508047.5 |